Meng Jiao

• Lead strategic initiative projects based on unmet medical needs and market opportunities, identifying high-potential targets, modalities, and therapeutic strategies to shape antibody pipeline innovation. • Oversee antibody discovery and early development programs, tracking progress, following up on key activities, and driving optimization across antibody engineering, platform development, and candidate evaluation. • Maintain timely cross-regional communication with China teams and BD licensing teams on project updates, scientific insights, and market trends to support alignment, strategy, and business development.

• Played a key role in building the Antibody Drug Development platform at Biocytogen Boston site from the ground up. • Took rapid initiative to confirm the first high-priority project. • Established end-to-end platform workflows spanning plasmid construction, protein expression, purification (AKTA), quality control (HPLC), and downstream antibody validation, including in vitro/ex vivo activity and functional assays such as binding, blocking, and internalization assays. • Coordinated with the China team to support biophysiochemical analysis and data alignment across sites. • Design and lead in vivo validation, coordinating animal breeding requests with the Beijing team to ensure on-time delivery and support program advancement.

--Translational research on target discovery and development • Identified a target through genome-wide CRISPR screening to potentiate immune checkpoint blockade (ICB) therapy; Unraveled the intrinsic and acquired mechanisms of mutation-mediated lung tumor resistance to ICB treatments; Developed a biologic-based therapy to combat resistance with preclinical and clinical evidence. (Manuscript in submission 2024; Nature 2020) • Tested compound combinations and developed a targeted therapy to enhance glioma sensitivity to radiotherapy; Revealed unique tumor signaling and immune responses to drug treatments by next-generation sequencing and computational analysis. (Cancer Res 2024) • Drove in-depth computational analysis of clinical data from various cohorts. Identified a target and a subsequent pro-inflammatory pathway that boosts anti-tumor immunity (iScience 2024) --Collaboration and project management • Fostered cross-functional collaborations with core facility staff, data scientists, and clinicians to provide translational insights into patient stratification and drive the development of targeted and combination therapies. Supported three phase I/II clinical trials. • Collaborated with the legal team on patent filing and the legal contract office to access clinical data. • Skilled in project management and effective communication. Supported two projects with timely reports to meet grant milestones; Mentored two medical students to ensure the completion of two projects. --Skill advancement • Extensive expertise in isolating, culturing, and engineering patient-derived samples (i.e., lung and colon tumors, NK, T), preclinical primary cells, and cell lines. Hands-on experience in tumor and immune cell characterization. • Certified in translational omics data analysis (Purdue University 2018) and data analytics (Google 2024) with proficiency in data mining and analysis.

• Led mechanistic studies to identify signaling pathways crucial for cancer invasion. • Established cell reprogramming with genetic modification, mechanical stress, and drug treatments. • Built a 3D culture model to study mesenchymal-to-amoeboid transition (MAT) for cancer metastasis and traced cell transition via live-cell imaging and fluorescent microscopy. • Conducted cell/non-cell-based assays to determine protein-protein interactions, protein binding sites, and binding affinity. • Adopted CRISPR/Cas9 when just developed to generate knockout cells for functional analysis.

- Mentored three graduate/undergraduate students with experimental design, data analysis, and troubleshooting for cell cycle and cell migration studies. - Developed cell-based assays and determined the roles of target protein in cell plasticity and breast cancer metastasis.

-Taught over 200 pre-med students and guided practical lab activities in Introductory Biology I lab (BISC 1413) and Introductory Biology II lab (BISC 1414).

- Designed and generated plasmids encoding target genes and studied the impact of juvenile hormone (JH) signaling in drosophila metamorphosis. - Predicted and identified regulatory elements (RE) upstream of target genes with computational protein alignments toolkit and determined conserved RE sites that maintain normal metamorphosis.

- Identified the critical sites of target protein for dimerization in leukocyte recruitment and activation. - Determined the metabolic responses of engineered leukocytes by HPLC-MS.

- Contributed to large-scale antibody production and characterization. - Performed serum preparation, and antigenicity tests using immunoassays (i.e. serum bactericidal assays, ELISA).